Emergent BioSolutions Inc. — Q2 2022 Form 10-Q
Reporting period: Three and six months ended June 30, 2022. Emergent is a life sciences company with Government Medical Countermeasures and commercial product businesses, plus contract development and manufacturing (CDMO) services.
Financial performance
| Metric | Q2 2022 | Q2 2021 | Six months 2022 | Six months 2021 |
|---|---|---|---|---|
| Revenue | $242.7 million | $397.5 million | $550.2 million | $740.5 million |
| Operating income (loss) | $(72.0) million | $14.5 million | $(65.6) million | $109.9 million |
| Net income (loss) | $(56.4) million | $4.6 million | $(60.1) million | $74.3 million |
| Diluted EPS | $(1.13) | $0.09 | $(1.19) | $1.37 |
| Operating cash flow | Not separately presented | Not separately presented | $(52.9) million | $(24.6) million |
- Q2 revenue fell 39%; six-month revenue fell 26%. Product sales rose 31% in Q2 and 49% for the half, led by anthrax vaccine deliveries and other products. Nasal naloxone sales declined 4% in Q2 amid generic competition, although half-year sales increased 8%.
- CDMO revenue fell sharply: Q2 was negative $1.8 million, versus $190.9 million a year earlier; six-month revenue was $59.0 million, down from $374.7 million. The comparison reflects the end of the BARDA COVID-19 capacity arrangement in November 2021, reduced manufacturing activity, and the Janssen contract dispute.
- Q2 gross margin for Products was $146.2 million; Services gross margin was negative $80.6 million. Services adjusted gross margin included a $12.7 million accelerated depreciation charge related to Janssen. Consolidated operating loss was $72.0 million.
- Cash and cash equivalents were $358.1 million at June 30, down from $576.1 million at year-end. Working capital was $807.5 million. Cash used in investing was $64.3 million and cash used in financing was $101.2 million for the first half.
- Debt carrying amount was $825.2 million, including $31.6 million current and $793.6 million long-term; gross debt before issuance costs was $832.7 million. No revolving-credit borrowings were outstanding; $598.7 million of capacity was available. Management reported compliance with debt covenants and believed liquidity was sufficient for the next 12 months.
- Inventory increased to $425.5 million from $350.8 million, including $126.2 million of Janssen-related raw materials that Emergent expects Janssen to reimburse. The company repurchased $81.9 million of stock during the first half.
Material changes, outlook and risks
- Janssen dispute: In June, Emergent alleged Janssen breached the manufacturing agreement; Janssen issued a termination notice alleging Emergent breaches, which Emergent disputes. Emergent reversed $13.3 million of previously recognized revenue and recorded $12.7 million accelerated depreciation. The parties disagree over amounts due; the company has not recorded a contingent liability for Janssen’s allegations. The filing reports no related billed or unbilled net receivable at quarter-end.
- Acquisition: Emergent agreed to acquire worldwide rights to brincidofovir, including TEMBEXA, from Chimerix for $225 million at closing, plus up to $100 million in procurement-option milestones and other potential payments and royalties. Closing was expected in Q3 2022 and was subject to conditions, including execution of a BARDA procurement contract.
- Operating outlook: The filing provides no clear quantitative full-year revenue or earnings guidance. Management cited variability in product delivery timing, government appropriations, CDMO activity and customer needs. Approximately $545.1 million of future contract value remained on unsatisfied performance obligations; most was expected to be recognized within 24 months, subject to timing changes.
- Risks and contingencies: Key risks include government procurement and funding decisions; manufacturing quality and regulatory compliance; CDMO customer demand and contract execution; generic competition for NARCAN; supply-chain constraints; debt covenant and refinancing risk; and COVID-19-related uncertainty. Securities and shareholder derivative litigation and multiple government inquiries related to manufacturing capabilities remained ongoing; potential losses were not reasonably estimable. Teva’s challenge to NARCAN patents had been decided against Emergent, and its rehearing petition was denied in May 2022.
- Despite a pretax loss, the company recorded income tax expense of $26.4 million in Q2 and $26.5 million for the first half. The filing does not explain a single straightforward cash-tax or effective-rate figure for these loss periods; review the tax footnote for the full reconciliation.
Important facts for investors to verify
- Resolution and financial impact of the Janssen termination dispute, including recovery of $126.2 million in raw materials and related non-cancelable orders.
- Whether the Chimerix/TEMBEXA transaction closed, whether the required BARDA contract was obtained, and the resulting purchase and milestone obligations.
- CDMO revenue recovery and facility utilization after the BARDA arrangement ended and Janssen activity stopped; assess Services’ negative Q2 adjusted gross margin.
- Government procurement timing and funding for anthrax vaccines, ACAM2000 and other medical countermeasures, alongside NARCAN generic-market effects.
- Cash burn, inventory growth, share repurchases, liquidity and compliance with credit-facility covenants as results develop.
- Progress and potential outcomes of shareholder litigation, government investigations, and manufacturing quality and compliance remediation.